Seeking Alpha

Trevor Lowenthal

 
View as an RSS Feed
View Trevor Lowenthal's Articles BY TICKER:
  • Provectus' Latest Developments Spark Investor Interest -- CFO/COO Culpepper Explains Why
    Today, 4:06 PM PVCT 6 Comments

    Summary

    • Provectus is an emerging, but contentious stock within the biopharmaceutical industry.
    • To followup with management, I conducted a second email interview to provide investors with further insight into the company's latest developments.
    • I interviewed Peter Culpepper, CFO and COO of Provectus.
  • Update: Opexa Q2 Earnings - Stock Down, But Buyout Thesis Remains Intact
    Fri, Aug. 15 OPXA 1 Comment

    Summary

    • Opexa reported Q2 earnings on August 14, 2014.
    • Despite the earnings miss, which raises my concern over increasing losses, I remain bullish on Opexa.
    • As anticipated, the progression of Tcelna for Secondary Progressive Multiple Sclerosis remains on course.
  • Update: Rexahn Q2 Earnings - Stock Down, But My Optimism Remains Intact
    Fri, Aug. 15 RNN 5 Comments

    Summary

    • Rexahn reported earnings for Q2 on August 14, 2014.
    • I reiterate my bull thesis on Rexahn, given the progression of its core clinical programs, and a solid cash position that should provide enough runway into 2016.
    • Continued progression of its core clinical programs occurred as expected, and Rexahn is on track to achieve several value driving catalysts that cannot be overlooked.
  • Update: Ligand's New License Agreement Strengthens Portfolio
    Thu, Aug. 14 LGND 14 Comments

    Summary

    • Ligand announces new license agreement with Avion Pharmaceuticals.
    • As a result, I reiterate my bull thesis on Ligand, as Captisol continues to gain traction in the industry.
    • I anticipated that Ligand would augment its royalty platform going into Q3 2014. The latest announcement corroborates this position.
  • Update: MannKind Q2 Earnings - Stock Sent To The Woodshed
    Wed, Aug. 13 SNY, MNKD 28 Comments

    Summary

    • MannKind reported earnings for Q2 on August 11, 2014.
    • Despite a massive drop in share price following the earnings event, I remain bullish on MannKind in light of the licensing agreement with Sanofi for Afrezza.
    • I anticipated a decline following the approval of Afrezza, as well as rising operating expenses and cash burn. The Q2 earnings report corroborates this assessment.
  • Update: Merrimack Earnings - Looming Concerns Still Remain
    Mon, Aug. 11 SNY, MACK 8 Comments

    Summary

    • Merrimack reported earnings for Q2 Monday, August 11.
    • Based on this event, I reiterate my bear thesis on Merrimack.
    • Despite the earnings beat (which I didn't anticipate), I remain unconvinced of Merrimack's commercial prospects.
  • Update: MannKind Enters Licensing Agreement - Is The Giant Leap Now Made Possible?
    Mon, Aug. 11 MNKD, SNY 40 Comments

    Summary

    • MannKind announces a newly formed licensing arrangement with Sanofi early Monday.
    • On this note, I reiterate my bull thesis on MannKind, given that it has successfully acquired an international partner to market Afrezza.
    • I anticipated a partnership would take place shortly after approval. The news release corroborates this position.
  • Update: Oragenics Earnings - Slow Q2 Revenue Growth Supports Restructuring
    Sun, Aug. 10 OGEN 8 Comments

    Summary

    • Oragenics reported earnings for Q2 on August 7, 2014.
    • I reiterate my bull thesis on Oragenics in the wake of continued development of Mu1140, and a strong cash position to sustain R&D through March, 2015.
    • I anticipated the company's latest efforts to reallocate resources to bolster the development of Mu1140, as well as its probiotic program. The latest earnings report corroborates this position.
  • Update: BioLife Q2 Earnings - Strong Growth Reaffirms Bull Thesis
    Fri, Aug. 8 BLFS 4 Comments

    Summary

    • BioLife reported earnings for Q2 2014 on August 7.
    • I reiterate my bull thesis based on rising core product revenues and growing margins.
    • I anticipated increased product sales of BioLife's biopreservation media this quarter. The Q2 earnings report corroborates this position.
  • Update: OXiGENE Earnings - Q2 Miss Challenges My Patience
    Wed, Aug. 6 OXGN 7 Comments

    Summary

    • OXiGENE reported Q2 earnings yesterday, missing analyst estimates.
    • In spite of this event, I reiterate my bull thesis on OXiGENE in light of the latest pipeline developments, which, in my opinion, counteract the negative earnings sentiment.
    • While I anticipated important updates regarding EU requirements and scheduling of the full readout for Zybrestat/Avastin, I didn't anticipate the earnings miss. The latest earnings report corroborates this position.
  • Update: China Biologic Products - Strong Q2 Earnings Growth
    Wed, Aug. 6 CBPO 3 Comments

    Summary

    • China Biologic Products reported Q2 earnings on August 5, surpassing expectations on many fronts.
    • Based on this event, I reaffirm my bull thesis on China Biologic Products.
    • In my earnings preview report, I expected increasing awareness would have a favorable impact on earnings growth for Q2. The earnings report confirms this assessment.
  • China Biologic Products Earnings Preview
    Tue, Aug. 5 CBPO 4 Comments

    Summary

    • China Biologic Products is a relatively unknown mid cap listed on the Nasdaq.
    • Following lackluster earnings in Q1 2014, the company is attempting to recuperate in Q2.
    • With the Q2 earnings report taking place after the market closes on August 5, here is what you need to know about this stock.
  • Update: Ligand Earnings - Strong Q2-Growth Beats Expectations
    Mon, Aug. 4 AMGN, LGND 3 Comments

    Summary

    • Ligand surpasses expectations for Q2 2014.
    • Based on this event, I reiterate my bull thesis on Ligand.
    • I anticipated strong performance as royalty payments to Ligand increase. The earnings report corroborates this position.
  • Update: Baxter's Earnings Beat Reaffirms Bull Thesis
    Fri, Aug. 1 BAX 5 Comments

    Summary

    • Baxter surpasses analyst expectations for Q2, 2014.
    • Based on this event, I reaffirm my bullish thesis on Baxter.
    • I anticipated moderate growth in my initial June report, and Baxter's latest quarterly report corroborates this position.
  • Update: AstraZeneca's Earnings Beat Reaffirms Bull Thesis
    Fri, Aug. 1 PFE, AZN 7 Comments

    Summary

    • AstraZeneca is attempting to make an earnings comeback after being hindered by a series of patent expirations, which has taken a toll on revenues.
    • Pfizer isn't budging with respect to unveiling whether it still has plans to acquire AstraZeneca after the 3-to-6-month waiting period.
    • Regardless, AstraZeneca is proving that it can exceed expectations independent of Pfizer, pursuant to the latest earnings report. Thus, I reaffirm my bull thesis in light of strong earnings performance.
  • BioLife: New Contract Manufacturing Agreement Is Undervalued - CEO Michael Rice Explains Why
    Thu, Jul. 31 BLFS 4 Comments

    Summary

    • BioLife is an emerging life sciences company listed on the Nasdaq.
    • I recently provided a stock update on Monday, given the new contract manufacturing agreement with Somahlution, as well as a new clinical customer announced several weeks ago.
    • In order to gain more insight on recent events, I conducted an email interview with Michael Rice, CEO of BioLife.
  • Ligand: Pipeline Breakdown Reveals Bullish Outlook
    Wed, Jul. 30 TGTX, LGND 9 Comments

    Summary

    • Ligand is an emerging biopharmaceutical company listed on the Nasdaq.
    • With more than 90 shots on goal and several revenue driving opportunities in 2014 alone, investors should watch it very closely.
    • Wall Street is overlooking the fact that Ligand's partners will spend $800 million in R&D, which clearly validates the Captisol technology platform.
    • The recent selloff is overdone, but regardless, investors should approach Ligand with a long-term mentality, since it ultimately thrives on a royalty-based business model.
  • Wall Street Is Overlooking Intellipharmaceutics- CFO Shameze Rampertab Tells Us Why
    Tue, Jul. 29 IPCI 49 Comments

    Summary

    • Intellipharmaceutics is an emerging pharmaceutical company listed on the Nasdaq.
    • It has a significant opportunity to market proprietary compounds within the controlled delivery space, namely Rexista oxycodone, which could be the best in class, abuse-deterrent opioid.
    • I conducted a conference call with Shameze Rampertab, Vice President of Finance and CFO of Intellipharmaceutics.
  • Update: BioLife's New Manufacturing Agreement And Additional Clinical Customer Reaffirms Bull Thesis
    Tue, Jul. 29 BLFS Comment!

    Summary

    • BioLife recently announces a 3-year contract manufacturing services agreement with privately held Somahlution LLC, offsetting the loss in manufacturing revenue from the since-terminated manufacturing agreement with Organ Recovery Systems.
    • In June, BioLife acquired an additional clinical customer, France-based TxCell, for its media biopreservation segment, bolstering its royalty portfolio for Cryostor by as much as $2 million/year post regulatory approval.
    • As a result, I'm updating my bull thesis and reaffirming why I think BioLife remains a highly undervalued company operating in the life sciences industry.
  • Update: CEO Departure And Recent Capital Raise At OXiGENE Reaffirms Bull Thesis
    Mon, Jul. 28 OXGN 18 Comments

    Summary

    • OXiGENE conducts recent $16 million secondary to bolster cash position and progress with likely Phase 3 study of its potential blockbuster Zyberstat/Avastin combination therapy.
    • The resignation of longtime CEO Peter Langecker and the appointment of experienced biotech executive Dr. David Chaplin could indicate a shifting of tides at OXiGENE to enhance shareholder value.
    • As a result, I'm updating my bull thesis and reaffirming why I'm still long on OXiGENE shares.
  • Is Now The Time To Buy Merrimack Pharmaceuticals?
    Tue, Jul. 8 SNY, MACK 36 Comments

    Summary

    • Merrimack has multiple shots on goal, but the odds of success are still against it.
    • Recent events surrounding MM-121 cannot be taken lightly, and investors must consider the fact that the drug could lack potential.
    • I think the bottom line is whether Merrimack's prospects can be rooted in the success of one drug, which has its own relevant implications.
    • For these reasons, I think time is the prospective investor's best friend here, since it shouldn't hurt to simply wait on the sidelines until more unravels.
  • Northwest Biotherapeutics Gets Called Out: Should Investors Worry?
    Mon, Jun. 23 NWBO 121 Comments

    Summary

    • Northwest Biotherapeutics plummets more than 17% for touting positive interim results.
    • Is the market responding appropriately?.
    • To answer this question, here are several important things investors need to know.
  • Is A Giant Leap For MannKind Possible?
    Tue, Jun. 10 MNKD 164 Comments

    Summary

    • MannKind Corporation is an emerging biopharmaceutical company listed on the Nasdaq GM.
    • With a short position of around 68 million and lopsided options activity, it appears that many professionals are positioning for a drop following the July 15 PDUFA binary event.
    • The standard buy-and-hold strategy exposes investors to extensive risk, leading me to conclude that an options strategy that provides significant upside potential with downside protection is far superior.
  • AstraZeneca: Pfizer Wants It, So Should You
    Tue, Jun. 10 NVS, PFE, TEVA 6 Comments

    Summary

    • AstraZeneca tumbled after rejecting Pfizer's "final" bid, and considerable risks remain.
    • Nevertheless, both its impressive dividend yield of 5.30% and extensive pipeline keep me interested.
    • To take advantage of its high yield, I have constructed a conservative yield-enhancing strategy that reduces risk and provides investors with peace of mind.
  • Inovio Pharmaceuticals Could Outperform - Dr. J. Joseph Kim, CEO, Tells Us Why
    Mon, Jun. 9 INO 83 Comments

    Summary

    • Inovio is an emerging biopharmaceutical company listed on the NYSE MKT.
    • Its novel HPV immunotherapy is the subject of the upcoming Phase II efficacy data release that will undoubtedly be a binary event.
    • Management seems very confident in the company's future prospects. I reached out to Dr. J. Joseph Kim, CEO of Inovio, to gain more insight.
  • Interview: Ligand Management Says Product Diversification Reduces Its Risk
    Mon, Jun. 9 LGND Comment!

    Summary

    • Ligand Pharmaceuticals is an emerging biopharmaceutical company listed on the Nasdaq.
    • With more than 90 shots on goal and several revenue driving opportunities in 2014 alone, investors should watch it very closely.
    • In order to gain more insight on this opportunity, we reached out to Matthew W. Foehr, executive vice president and chief operating officer.
  • Provectus Management Responds To Accusations
    Fri, Jun. 6 PVCT 83 Comments

    Summary

    • Provectus is an emerging, but contentious stock within the biopharmaceutical industry.
    • With accusations of stock promoting and "pump and dump" qualities, it is important to gain more insight from management concerning whether these allegations hold merit.
    • In order to attempt to do so, I reached out to CFO/COO Peter Culpepper, and Dr. Eric Wachter, CTO of Provectus.
  • Baxter International - A Yield-Enhancing Strategy On A Diversified Healthcare Corporation
    Mon, Jun. 2 BAX 8 Comments

    Summary

    • Shares are trading near 52-week highs, but the recent insider selling prompts downside concerns that must be taken into consideration.
    • While there is no margin of safety at current levels, a conservative options strategy limits risk, while enhancing the current yield of 2.80%.
    • The company has a five-year dividend growth rate of 16.4%, and seven successive years of dividend growth.
  • Interview With Dr. Geert Cauwenbergh, President And CEO Of RXi Pharmaceuticals
    Mon, Jun. 2 RXII 5 Comments

    Summary

    • RXi is an emerging micro cap listed on the Nasdaq CM.
    • It has a significant opportunity to market self-delivering RNAi compounds, which could fill a largely unmet medical need in wound healing.
    • We reached out to Dr. Geert Cauwenbergh, president and chief executive officer of RXi, for further insight on this opportunity.
  • Interview With Mike Sherman, Chief Financial Officer Of Endocyte
    Mon, Jun. 2 MRK, ECYT 7 Comments

    Summary

    • Endocyte is an emerging oncology play listed on the Nasdaq GS.
    • The Phase I trial of EC1456 is progressing well, and management remains optimistic, despite the termination of the Phase III PROCEED Trial.
    • We reached out to Mike Sherman, Chief Financial Officer of Endocyte, for further insight on this opportunity.
  • BioLife Solutions: A Heavily Discounted High Growth Opportunity
       • Fri, May. 23 BLFS 23 Comments

    Summary

    • BioLife is a virtually unknown micro cap listed on the Nasdaq.
    • With 100 clinical stage products and therapies using its biopreservation media products, we project that the company could generate around $69 million by 2022.
    • As the company embarks on an exhaustive investor relations program in 2014, the company should attract more retail and institutional investors.
    • Three insiders have bought shares on the open market around current price levels this month, while none have sold this quarter. We believe this is a strong bullish signal.
    • As a result, we believe the company is significantly undervalued, and shares could trade higher soon.
  • Rexahn Pharmaceuticals: An Undervalued Oncology Play With Risk Diversification
       • Wed, May. 14 RNN 16 Comments

    Summary

    • Rexahn is an emerging biopharmaceutical company listed on the NYSE MKT.
    • RX-3117 could have a profound impact on patients with Gemcitabine-resistant forms of cancer.
    • Investors should be aware that a partnership for the compound could be announced any time during mid-2014, which could drive shares substantially higher.
    • The latest market correction offers a rare and unique opportunity to accumulate the stock at a 34% discount. However, this opportunity is fleeting since shares could trade higher soon.
    • With three drug candidates targeting different cancer cells, Rexahn has a 50% to 75% shot at receiving FDA approval for only one compound. Thus, its risk dynamic is diversified.